CAPTRUST Financial Advisors
LCTX icon

CAPTRUST Financial Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-678
Closed -$2K – 5034
2021
Q4 		$2K Hold
678
– – ﹤0.01% 4419
2021
Q3 		$2K Sell
678
-58
-8% -$149 ﹤0.01% 4273
2021
Q2 		$2K Buy
736
+678
+1,169% +$1.75K ﹤0.01% 4185
2021
Q1 		$0 Hold
58
– – ﹤0.01% 4424
2020
Q4 		$0 Hold
58
– – ﹤0.01% 3461
2020
Q3 		$0 Hold
58
– – ﹤0.01% 3154
2020
Q2 		$0 Buy
+58
New +$51 ﹤0.01% 2874

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

CAPTRUST Financial Advisors's LCTX Position: Q1 2022 in Review

CAPTRUST Financial Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q1 2022, closing a stake of 678 shares — an estimated $2K sold.

CAPTRUST Financial Advisors first reported a position in LCTX in Q2 2020 and held it in 7 quarters. The position peaked at $2K in Q4 2021. 110 funds tracked by Wall St. Rank hold LCTX as of Q1 2022.

  • CAPTRUST Financial Advisors reported no remaining Lineage Cell Therapeutics position as of Q1 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 678 Lineage Cell Therapeutics shares in Q1 2022, an estimated $2K.
  • CAPTRUST Financial Advisors first reported a position in Lineage Cell Therapeutics in Q2 2020 and held it in 7 quarters.
  • CAPTRUST Financial Advisors's Lineage Cell Therapeutics position peaked at $2K in Q4 2021.
  • 110 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2022, filed 16 May 2022.